Planet Briefing

First published · Last updated

MA08.04 Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations

A journal article reports Phase 2 interim results for zipalertinib in patients with non-small cell lung cancer (NSCLC) carrying uncommon non-exon 20 insertion EGFR mutations. The supplied excerpt does not include any outcome data or trial results.

Immunotherapy phase III studies in the first line treatment of Non-Small Cell Lung Cancer (NSCLC), includes Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150. https://doi.org/10.3390/ph13110373
Illustrative image: Immunotherapy phase III studies in the first line treatment of Non-Small Cell Lung Cancer (NSCLC), includes Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150. https://doi.org/10.3390/ph13110373 — First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373./Wikimedia Commons, CC BY-SA 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
2/10
Geographic reach
1/10
Global importance
3/10
Impact magnitude
3/10
Positivity
5/10
Urgency
2/10

Why it matters

This interim report documents ongoing clinical research into a targeted therapy for a specific subset of NSCLC patients.

Sources

Report an issue